{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gastroenteritis/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"ddc9423c-8dd0-5c5b-b208-f261c2cd777d","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 114c6f6a-437e-47e9-a93d-63e611c2bcb9 --><h2>Clarithromycin</h2><!-- end field 114c6f6a-437e-47e9-a93d-63e611c2bcb9 -->","summary":"","htmlStringContent":"<!-- begin item 9c06e126-0785-47c2-ae0c-47af1b071a95 --><!-- end item 9c06e126-0785-47c2-ae0c-47af1b071a95 -->","topic":{"id":"b4861e4a-0cf5-5fed-b83a-a57e60b78a80","topicId":"f3241704-6943-4c6f-9689-cf06812d0832","topicName":"Gastroenteritis","slug":"gastroenteritis","lastRevised":"Last revised in August 2020","chapters":[{"id":"6d884ff2-d64b-55ab-aae4-78f940a95f30","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b8c6f38-638e-5804-8318-e1b14304e522","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"94101b20-12cb-5041-a413-6dcc12af895e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f4287eb4-029e-5263-ae00-6b8ece9aff32","slug":"changes","fullItemName":"Changes"},{"id":"4d578aaa-9662-5914-903d-e36514be32a0","slug":"update","fullItemName":"Update"}]},{"id":"d01dac38-120c-51d7-a620-b85d40b1eb15","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd1552a6-5a2d-563b-a242-29bd94992517","slug":"goals","fullItemName":"Goals"},{"id":"b7b0c03c-8588-5565-82d9-9cfe2d111d41","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b32a632a-610d-59de-bf5f-d79f466a66b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"28e54d5a-177d-5e18-9753-67134efb41a6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2b2f62eb-7996-5b9c-88ed-3648b2e3721d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"1e2a0d5e-dba9-54fe-99e1-1e33dd814faa","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d382f491-ad27-5dbc-bfa7-806501a73eb5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6b1334e-cda3-5363-a887-f24bcde0b626","slug":"definition","fullItemName":"Definition"},{"id":"501c659b-1656-5ad1-b381-f3042ed81bec","slug":"causes","fullItemName":"Causes"},{"id":"2e6d28a0-305f-5c3c-983a-62e1631c41b8","slug":"complications","fullItemName":"Complications"}]},{"id":"71e06d5f-9179-5a88-986f-34fd82eab600","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"de24a8b0-cda2-5be8-8fbf-df6ddf6fb6eb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3f17076e-616a-532c-a5ee-d6a5d2104dc5","slug":"assessment","fullItemName":"Assessment"},{"id":"bf8cbeb8-b0a5-5ebc-9cfc-7ba3beb62c6b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"34db7d00-7fa0-5e11-a2b2-0e045c80e236","fullItemName":"Management","slug":"management","subChapters":[{"id":"64ea9cd1-ae9b-5d77-bc7b-1df0c42b3d66","slug":"child-gastroenteritis","fullItemName":"Scenario: Child gastroenteritis"},{"id":"97ae699a-60c4-5649-a4ad-f0bbdf5c7aa5","slug":"adult-gastroenteritis","fullItemName":"Scenario: Adult gastroenteritis"}]},{"id":"3874a053-755a-5518-961d-b6811d36d278","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6969159-fdcf-5f1f-ac9a-c8bcf291abdc","slug":"tinidazole","fullItemName":"Tinidazole"},{"id":"ddc9423c-8dd0-5c5b-b208-f261c2cd777d","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"84f507dc-726d-559a-b788-9c91297b0fd0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2e6aa3b5-4c48-538f-bc1e-8c97a0e4940e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"60c6fc26-4bfa-5e0d-bba6-0ebffc61d83b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0cb4826a-19bb-549f-b65f-2f5ad75883bc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b05f7822-56ab-538c-9fb0-fd20a99810a2","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8bc3886a-0fd7-52a0-9be2-506de8584bc9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a0898f71-226b-5af6-87b5-20b9c6c1fe78","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52fa5fd-99e9-5dd5-b626-0e429b2424e3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3874a053-755a-5518-961d-b6811d36d278","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c31f7499-f3bf-5cd5-9222-d512f81e3d56","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 61009a3d-d896-4928-94d6-ac1200dfed6f --><h3>Contraindications and cautions</h3><!-- end field 61009a3d-d896-4928-94d6-ac1200dfed6f -->","summary":"","htmlStringContent":"<!-- begin item 22cd620f-e27f-49ac-8bac-ac1200dfed35 --><!-- begin field 826db0dc-7424-4a56-adc8-ac1200dfed6f --><ul><li><strong>Do not prescribe clarithromycin to:</strong><ul><li>People with severe hepatic impairment if renal impairment is also present.</li><li>Pregnant women, especially in the first trimester, unless the potential benefit outweighs the risk.</li><li>Breastfeeding women — the manufacturer advises to avoid unless the potential benefit outweighs the risk, as it is present in breast milk.</li></ul></li><li><strong>Prescribe clarithromycin with caution to people with:</strong><ul><li>Electrolyte disturbances (predisposition to QT interval prolongation); or other predisposition to QT interval prolongation.</li><li>Myasthenia gravis — may aggravate symptoms.</li><li>People with hepatic impairment.</li><li>People with renal impairment — use half normal dose if the estimated glomerular filtration rate (eGFR) is less than 30 mL per minute per 1.73 m<sup>2</sup>; maximum duration 14 days.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 826db0dc-7424-4a56-adc8-ac1200dfed6f --><!-- end item 22cd620f-e27f-49ac-8bac-ac1200dfed35 -->","subChapters":[]},{"id":"f23e9cae-1786-541e-85ab-7e69d0a24e35","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 79e66d9f-7242-406e-8019-ac1200dff807 --><h3>Adverse effects</h3><!-- end field 79e66d9f-7242-406e-8019-ac1200dff807 -->","summary":"","htmlStringContent":"<!-- begin item 2d6c66d3-bfe8-4b38-a77a-ac1200dff7e5 --><!-- begin field f2a018bc-0759-4949-9ec6-ac1200dff807 --><p><strong>Possible adverse effects of clarithromycin include:</strong></p><ul><li>Reduced appetite, diarrhoea, dizziness, gastrointestinal discomfort, gastrointestinal disorders, nausea, and vomiting.</li><li>Headache, hearing impairment, insomnia, pancreatitis, paraesthesia, skin reactions, altered taste, vasodilation, vision disorders.</li><li>Burping, dry mouth, muscle symptoms, oral disorders, thrombocytosis, tremor (uncommon).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f2a018bc-0759-4949-9ec6-ac1200dff807 --><!-- end item 2d6c66d3-bfe8-4b38-a77a-ac1200dff7e5 -->","subChapters":[]},{"id":"37f5cf6e-ea31-5d9e-886d-8ce10f640bf7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 35c5847b-e81e-4346-8d13-ac1200e0013e --><h3>Drug interactions</h3><!-- end field 35c5847b-e81e-4346-8d13-ac1200e0013e -->","summary":"","htmlStringContent":"<!-- begin item 34931370-b795-4314-8fa8-ac1200e00111 --><!-- begin field f9ef323e-47c3-403e-950e-ac1200e0013e --><p><strong>Possible drug interactions with clarithromycin include:</strong></p><ul><li>Aminophylline — aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Amiodarone — both clarithromycin and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Amisulpride — both clarithromycin and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Atorvastatin — clarithromycin is predicted to increase the exposure to atorvastatin. The manufacturer advises to avoid or adjust the dose and monitor for rhabdomyolysis.</li><li>Beclometasone — beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Bendroflumethiazide — betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Bromocriptine — clarithromycin increases the exposure to bromocriptine. The manufacturer advises to use with caution.</li><li>Budesonide — clarithromycin is predicted to increase the exposure to budesonide. The manufacturer advises to avoid or monitor for adverse effects.</li><li>Bumetanide — bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Buprenorphine — clarithromycin is predicted to increase the exposure to buprenorphine. The manufacturer advises to monitor and adjust the dose.</li><li>Cabergoline — clarithromycin is predicted to increase the concentration of cabergoline. The manufacturer advises to avoid.</li><li>Carbamazepine — clarithromycin slightly increases the concentration of carbamazepine. The manufacturer advises to monitor the concentration and adjust the dose.</li><li>Chlorpromazine — both clarithromycin and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Ciclosporin — clarithromycin increases the concentration of ciclosporin. The manufacturer advises caution.</li><li>Citalopram — both clarithromycin and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Clomipramine — both clarithromycin and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Colchicine — clarithromycin is predicted to increase the exposure to colchicine. The manufacturer advises to avoid potent inhibitors of CYP3A4 or adjust the colchicine dose.</li><li>Dexamethasone — dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin. Clarithromycin is predicted to increase the exposure to dexamethasone. The manufacturer advises to avoid or monitor for adverse effects.</li><li>Digoxin — clarithromycin increases the concentration of digoxin. The manufacturer advises to monitor the digoxin concentration.</li><li>Diltiazem — clarithromycin is predicted to increase the exposure to diltiazem. The manufacturer advises caution.</li><li>Domperidone — domperidone increases the risk of QT prolongation when given with clarithromycin. The manufacturer advises to avoid.</li><li>Edoxaban — clarithromycin is predicted to slightly increase the exposure to edoxaban.</li><li>Eplerenone — clarithromycin is predicted to markedly increase the exposure to eplerenone. The manufacturer advises to avoid.</li><li>Escitalopram — both clarithromycin and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Fentanyl — clarithromycin is predicted to increase the exposure to fentanyl. The manufacturer advises to monitor and adjust the dose.</li><li>Fesoterodine — clarithromycin is predicted to moderately increase the exposure to fesoterodine. The manufacturer advises to adjust the fesoterodine dose with potent inhibitors of CYP3A4; avoid in hepatic and renal impairment.</li><li>Flecainide — both clarithromycin and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Fluconazole — both clarithromycin and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Fludrocortisone — fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Fluticasone — clarithromycin is predicted to increase the exposure to fluticasone. The manufacturer advises to avoid or monitor for adverse effects.</li><li>Formoterol — formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Furosemide — furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Haloperidol — both clarithromycin and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Hydrocortisone — clarithromycin is predicted to increase the exposure to hydrocortisone. The manufacturer advises to avoid or monitor for adverse effects. Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Hydroxyzine — both clarithromycin and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Indapamide — indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Ivabradine — ivabradine is predicted to increase the risk of torsade de pointes when given with clarithromycin. The manufacturer advises to avoid. Clarithromycin is predicted to increase the exposure to ivabradine. The manufacturer advises to avoid.</li><li>Lercanidipine — clarithromycin is predicted to markedly increase the exposure to lercanidipine. The manufacturer advises to avoid.</li><li>Levomepromazine — both clarithromycin and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Lithium — both clarithromycin and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Mefloquine — mefloquine is predicted to increase the risk of QT prolongation when given with clarithromycin.</li><li>Methadone — both clarithromycin and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Clarithromycin is predicted to increase the concentration of methadone.</li><li>Methylprednisolone — methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin. Clarithromycin is predicted to increase the exposure to methylprednisolone. Manufacturer advises to avoid or monitor for adverse effects.</li><li>Metolazone — metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Midazolam — clarithromycin is predicted to markedly to very markedly increase the exposure to midazolam. The manufacturer advises to avoid or adjust the dose.</li><li>Mizolastine — mizolastine is predicted to increase the risk of QT prolongation when given with clarithromycin. The manufacturer advises to avoid.</li><li>Mometasone — clarithromycin is predicted to increase the exposure to mometasone. The manufacturer advises to avoid or monitor for adverse effects.</li><li>Moxifloxacin — both clarithromycin and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Ondansetron — both clarithromycin and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Oxycodone — clarithromycin is predicted to increase the exposure to oxycodone. The manufacturer advises to monitor and adjust the dose.</li><li>Pravastatin — clarithromycin moderately increases the exposure to pravastatin. The manufacturer advises caution.</li><li>Prednisolone — clarithromycin is predicted to increase the exposure to prednisolone. The manufacturer advises to avoid or monitor for adverse effects. Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Quetiapine — clarithromycin is predicted to increase the exposure to quetiapine. The manufacturer advises to avoid.</li><li>Quinine — both clarithromycin and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Ranolazine — both clarithromycin and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Rifampicin — rifampicin decreases the concentration of clarithromycin.</li><li>Risperidone — both clarithromycin and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Salbutamol — salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Salmeterol — salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin. Clarithromycin is predicted to increase the exposure to salmeterol. The manufacturer advises to avoid.</li><li>Sildenafil — both clarithromycin and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Simvastatin — clarithromycin is predicted to increase the exposure to simvastatin. The manufacturer advises to avoid.</li><li>Solifenacin — clarithromycin is predicted to increase the exposure to solifenacin. The manufacturer advises to adjust solifenacin dose; avoid in hepatic and renal impairment.</li><li>Sotalol — both clarithromycin and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Sulpiride — both clarithromycin and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Tacrolimus — clarithromycin is predicted to increase the concentration of tacrolimus. The manufacturer advises to monitor and adjust the dose.</li><li>Tadalafil — clarithromycin is predicted to increase the exposure to tadalafil. The manufacturer advises to use with caution or avoid.</li><li>Terbutaline — terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Theophylline — theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Ticagrelor — clarithromycin is predicted to markedly increase the exposure to ticagrelor. The manufacturer advises to avoid.</li><li>Tolterodine — both clarithromycin and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Torasemide — torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li>Ulipristal — clarithromycin is predicted to increase the exposure to ulipristal.</li><li>Venlafaxine — both clarithromycin and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation.</li><li>Verapamil — clarithromycin is predicted to increase the exposure to verapamil. The manufacturer advises to monitor.</li><li>Warfarin — clarithromycin increases the anticoagulant effect of warfarin. The manufacturer advises to monitor the international normalized ratio (INR) and adjust the dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gastroenteritis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f9ef323e-47c3-403e-950e-ac1200e0013e --><!-- end item 34931370-b795-4314-8fa8-ac1200e00111 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}